Marvin & Palmer Associates Inc Eli Lilly & CO Transaction History

Marvin & Palmer Associates Inc

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 09, 2022	BUY	$278.73 - $327.27 $8.84 Million - $10.4 Million	31,700 New	31,700 $10.3 Million
Q3 2020 Nov 12, 2020	SELL	$146.22 - $169.13 $4.23 Million - $4.89 Million	-28,918 Closed	0 $0
Q2 2020 Aug 13, 2020	BUY	$136.42 - $164.18 $3.94 Million - $4.75 Million	28,918 New	28,918 $4.75 Million
Q2 2019 Aug 19, 2019	SELL	$110.79 - $129.32 $4.82 Million - $5.62 Million	-43,467 Closed	0 $0
Q4 2018 Feb 12, 2019	BUY	$105.9 - $118.64 $4.6 Million - $5.16 Million	43,467 New	43,467 $5.03 Million

4,016

739M

8.27M

10.5M

Ticker LLY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 950,174,976
Market Cap $760B
Description
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, T...

Get notified when there are updates to the investment portfolio of Marvin & Palmer Associates Inc, based on Form 13F filings with the SEC.

Stay updated on Marvin & Palmer Associates Inc with notifications on news.